Bachmann-Bupp Syndrome

1. Disease Information

1.1 Overview

Bachmann–Bupp syndrome (BABS) is an ultra-rare autosomal dominant neurodevelopmental disorder caused by de novo gain-of-function variants in the 3′ end of ODC1, the gene encoding ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis. It is one of five recognized "polyaminopathies."

The canonical clinical triad is global developmental delay + hypotonia + a distinctive non-congenital alopecia (hair present at birth, then shed in large clumps within the first weeks of life), usually with macrocephaly/macrosomia, dysmorphic facies, and nonspecific brain MRI abnormalities.

"Bachmann-Bupp syndrome (BABS) is a neurodevelopmental disorder characterized by developmental delay, hypotonia, and varying forms of non-congenital alopecia. The condition is caused by 3'-end mutations of the ornithine decarboxylase 1 (ODC1) gene, which produce carboxy (C)-terminally truncated variants of ODC, a pyridoxal 5'-phosphate-dependent enzyme. C-terminal truncation of ODC prevents its ubiquitin-independent proteasomal degradation and leads to cellular accumulation of ODC enzyme that remains catalytically active." — Bachmann & Bupp, Dev Med Child Neurol 2024 (PMID:37469105)

BABS is of outsized translational significance because it is the first polyaminopathy with a viable targeted treatment: the ODC suicide inhibitor eflornithine (α-difluoromethylornithine, DFMO), repurposed from oncology/trypanosomiasis, moved from disease description (2018) to first patient dosed in 16 months (PMID:40167220).

1.2 Key identifiers

1.3 Synonyms

• Bachmann–Bupp syndrome (BABS) — the eponymic/clinical name in wide use
• Neurodevelopmental disorder with alopecia and brain abnormalities (NEDABA) — the MONDO/OMIM/MedGen preferred label
• ODC1-related neurodevelopmental disorder — GeneReviews dyadic name
• Global developmental delay–alopecia–macrocephaly–facial dysmorphism–structural brain anomalies syndrome — Orphanet label
• Gene aliases in NCBI: ODC, BABS, NEDBA, NEDBIA

1.4 Provenance of information

Essentially all knowledge is derived from individual patient reports and small case series, not from EHR-scale or registry-scale aggregation. The aggregating structures are: - GeneReviews chapter (Bupp, VanSickle, Bachmann; PMID:36007106, NBK583220) - The International Center for Polyamine Disorders (ICPD) — a Corewell Health / Michigan State University collaboration with the Snyder-Robinson Foundation, which performs "comprehensive data generation and local as well as remote sample collection from patients with known or suspected polyamine disorders around the world" (PMID:37092498) - A 2026 systematic narrative review of all five polyaminopathies (PMID:41410504)

There is no EHR-derived cohort, no ICEES/COHD comorbidity signal, and no population registry for BABS.

2. Etiology

2.1 Primary cause

Heterozygous, almost always de novo, gain-of-function variants clustered in the 3′ end of ODC1 — specifically in exon 12 or the intron 11 splice sites immediately preceding it — that remove or disrupt the C-terminal ~37-residue degradation domain (amino acids ~425–461) of the 461-aa ODC protein.

Because these variants fall in the last exon, the transcripts escape nonsense-mediated decay; a truncated but catalytically fully active ODC protein is produced that can no longer be degraded by the antizyme/26S-proteasome route. The result is massive cellular accumulation of active ODC and putrescine overproduction.

"We hypothesized that this new mutation (c.1342 A>T) leads to a C-terminal truncation variant of the ODC protein that is resistant to normal proteasomal degradation, leading to putrescine accumulation in cells." — Schultz et al., Biochem J 2019 (PMID:31249027)

This is a true molecular gain of function (protein stabilization → enzyme over-accumulation), not haploinsufficiency. Critically, ODC1 loss-of-function produces a mechanistically opposite and phenotypically distinct picture (see §4.4).

2.2 Genetic risk factors

• Causal variants: see §4.2. All reported pathogenic variants are 3′-end truncating/splice variants.
• Susceptibility loci / modifier genes: None identified. No GWAS, no reported modifiers.
• Parental age: Not studied. A paternal-age effect is plausible for a de novo dominant condition but has not been demonstrated for BABS.
• Family history: Essentially absent — all molecularly tested probands to date have de novo variants.

2.3 Environmental risk factors

None known. BABS is a monogenic Mendelian disorder with no established environmental contribution to occurrence. Polyhydramnios (58–80% of pregnancies) is a consequence, not a cause.

One theoretical, unproven environmental modifier exists on the downstream side: dietary and gut-microbial polyamines contribute meaningfully to the body polyamine pool, and Rodan et al. explicitly proposed them as therapeutic levers:

"Therapies aimed at reducing putrescine levels, including ODC1 inhibitors, dietary interventions, and antibiotics to reduce polyamine production by gastrointestinal flora could be considered as disease-modifying therapies." — Rodan et al., Am J Med Genet A 2018 (PMID:30475435)

This makes dietary polyamine load and gut flora composition biologically plausible severity modifiers, but no human data support this in BABS.

2.4 Protective factors

• Genetic protective factors: none identified.
• Environmental protective factors: none validated. Polyamine-restricted diets are listed by GeneReviews under "therapies under investigation," not as established protection.

2.5 Gene–environment interactions

No documented GxE interaction. The single actionable "interaction" is pharmacological: the disease phenotype is at least partly reversible by pharmacologic ODC inhibition (eflornithine), demonstrating that the phenotype depends on ongoing polyamine flux rather than solely on fixed developmental damage — a point strongly supported by both the human treatment response (PMID:34282722) and the K6/ODC mouse (PMID:8618048, see §15).

3. Phenotypes

3.1 Frequency table — GeneReviews cohort (n=9 published individuals; primary source)

Source: GeneReviews Table 2 (PMID:36007106, NBK583220).

3.2 Frequency table — 2026 systematic review (n=12 published BABS cases)

Source: VanSickle et al., Am J Med Genet A 2026 (PMID:41410504, PMC13270430, DOI 10.1002/ajmga.70029).

⚠️ Verification flag: the extracted percentages in this table were internally inconsistent for GDD (listed as "11/12 | 83.3%", where 11/12 = 91.7%). Re-verify the exact n/N against the published Table before committing frequencies from this source to the KB. The GeneReviews table (§3.1) is the safer primary frequency source.

3.3 HPO disease-annotation set (HPOA, OMIM:619075) — with explicit n/N and onset

Source: HPO annotation network, ontology.jax.org (OMIM:619075).

Orphanet-sourced HPOA bands (via Monarch, MONDO:0033642) additionally list as Frequent (HP:0040282): HP:0000400 Macrotia, HP:0001488 Bilateral ptosis, HP:0030890 Hyperintensity of cerebral white matter on MRI; and as Occasional (HP:0040283): HP:0000023 Inguinal hernia, HP:0000278 Retrognathia, HP:0001257 Spasticity, HP:0002465 Poor speech.

3.4 Per-phenotype characterization

Alopecia (the pathognomonic sign) — HP:0001596 / HP:0002293 - Type: physical/ectodermal manifestation - Onset: non-congenital, first weeks of life. GeneReviews: hair "is sometimes sparse and sometimes has atypical color" at birth, then lost "in large clumps" within weeks. Eyebrows and eyelashes are typically congenitally absent/sparse (HP:0002223, HP:0000653). - Severity/progression: variable; often near-total scalp alopecia. Reversible on eflornithine. - Frequency: 100% - QoL impact: cosmetic and psychosocial; hair regrowth is consistently reported by families as one of the most visible and valued treatment effects.

Global developmental delay / intellectual disability — HP:0001263, HP:0001249 - Onset: infancy - Severity: "moderate to severe range" (GeneReviews). Independent walking achieved between 17 months and 4 years; three reported individuals remained nonverbal at last report. A 12-year-old (Patient 10) had "moderate developmental delay and intellectual disability, with the ability to read and write" (PMID:37092498) — demonstrating real variable expressivity. - Progression: static/non-degenerative; improvement documented with treatment. - QoL impact: the dominant driver of lifelong disability, caregiver burden, and educational need.

Hypotonia — HP:0001290 / HP:0001319 - Onset: neonatal/infantile; Frequency: ~92–100%; Progression: generally static, improves with therapy and with DFMO. - One patient developed proximal myopathy confirmed on EMG with progressive weakness and wheelchair use for distance (PMID:37092498) — HP:0003701 Proximal muscle weakness.

Macrocephaly / overgrowth — HP:0000256, HP:0001520 - Onset: prenatal to infantile; the index patient had macrosomia and macrocephaly (PMID:30239107); Patient 10 had OFC >99th centile (38 cm) at birth. - Frequency: 66–75%. Absolute or relative macrocephaly (Rodan et al.). - Overgrowth may give way to obesity risk in later childhood (GeneReviews lists caloric management).

Brain MRI abnormalities — HP:0012443 - Frequency: abnormal in essentially all imaged patients, but without a consistent pattern.

"Every patient had a brain MRI performed at some time point, and neuroimaging abnormalities are common, but not with a particular pattern or recurrence of findings." — VanSickle et al. 2021 (PMID:34477286) - Reported findings: white matter signal abnormality (HP:0002500 / HP:0030890), prominent Virchow-Robin/perivascular spaces (HP:0012520), periventricular and germinal-matrix cysts (HP:0007109), porencephalic cysts (HP:0002132), corpus callosum abnormalities incl. hypoplasia of the mid-body (HP:0002079), ventriculomegaly (HP:0002119), cerebellar vermis dysgenesis (HP:0002195), focal polymicrogyria (HP:0032471), cerebral calcification (HP:0002514), hypoplastic optic chiasm, hippocampal volume loss.

Seizures/epilepsy — HP:0001250 - Rare (1/12, 8.3%) but can be severe and late-onset. The oldest reported patient (male, 23 y) developed absence seizures at age 14, evolving to "multiple seizure types but atypical absence, atonic, and generalized tonic–clonic," refractory to ketogenic diet and multiple ASMs (PMID:34477286). This was the first epilepsy report in BABS. - Contrast: epilepsy is far more prominent in Snyder-Robinson syndrome (~63%), which is a useful discriminator (PMID:41410504).

Behavioral phenotypes - ADHD (HP:0007018, 2/3 in HPOA), autism spectrum disorder (HP:0000717), aggression (HP:0000718). Aggregate ADHD/ASD ~33%.

Dermatologic (beyond alopecia) - Follicular cysts (~50% with skin findings), keratosis pilaris (HP:0032152), dry skin (HP:0000958), hypoplastic/small nails (HP:0001792). Follicular cysts directly phenocopy the K6/ODC mouse.

"In both patients, treatment with difluoromethylornithine has resulted in improved dermatologic signs, including regrowth of eyebrow and scalp hair and cessation of recurrent follicular cyst development." — Afrin et al., Pediatr Dermatol 2023 (PMID:36443247)

Feeding / GI - Feeding difficulties in infancy (HP:0008872), aspiration (HP:0002835), constipation (HP:0002019, 37.5%). NG/G-tube may be required.

Sensory - Sensorineural hearing loss (HP:0000407) — present in index patient; refractive error and strabismus (HP:0000486) warrant annual ophthalmology.

Prenatal - Polyhydramnios (HP:0001561) 55–80%, decreased fetal movement (HP:0001558), prenatal ventriculomegaly/cerebral cysts, and — in one 2026 report — macrocephaly plus ventricular septal defect (HP:0001629) detected on second-trimester ultrasound (PMID:41931584).

Genitourinary/skeletal - Cryptorchidism (HP:0000028, 2/3), inguinal hernia (HP:0000023), fifth-finger clinodactyly (HP:0004209), joint hypermobility (HP:0001382).

3.5 Quality of life

No BABS-specific QoL instrument data (EQ-5D, PROMIS, SF-36, PedsQL) exist in the literature. QoL statements are qualitative and family-reported. Reported functionally meaningful post-treatment gains in the index patient — self-feeding with a spoon, sitting unsupported, walker use — are the closest available surrogates for QoL benefit (PMID:34282722, PMID:37469105). This is a genuine evidence gap.

4. Genetic / Molecular Information

4.1 Causal gene

4.2 Pathogenic variants (compiled from all sources)

All are heterozygous, de novo, germline, and all cluster in exon 12 / intron 11 of NM_002539.3 — the 3′ region encoding the C-terminal degron.

⚠️ Nomenclature verification flags for the curator: 1. One secondary source rendered the index variant as "c.1342A>G (p.Lys448*)". The primary paper and ClinVar both say c.1342A>T — use c.1342A>T. 2. Variants #5 and #7 have protein annotations that are inconsistent with their cDNA positions as extracted (c.1242_1263del22 → p.Trp414* and c.1313_1316del → p.438Rfs*9). Re-derive or re-verify from the source tables before committing HGVS protein strings. 3. c.1242-2A>G is the single recurrent variant and is the most likely candidate for a "hotspot" claim.

The instructive negative — functional testing overrides sequence intuition. Bupp et al. 2025 report a patient with the missense VUS c.1217A>T (p.Tyr406Phe) and an atypical presentation whose ODC enzyme activity was "not greater than unaffected control patients' samples," arguing against pathogenicity. This establishes that the biochemical assay, not the variant location alone, adjudicates BABS (PMID:40167220).

4.3 Variant classification, allele frequency, origin

• ACMG/AMP classification: BABS variants are classified Pathogenic. Note that PVS1 (null variant) is NOT the operative criterion here — the mechanism is gain-of-function via stabilization, so PS3 (functional evidence: elevated ODC protein/activity/putrescine), PS2 (de novo with confirmed parentage), PM1 (mutational hotspot in the C-terminal degron), and PP4 (highly specific phenotype) carry the weight. Applying PVS1 to an ODC1 3′-truncating variant would be a mechanistic error.
• Allele frequency: All reported BABS variants are absent from gnomAD/1000 Genomes/TOPMed (private de novo events). gnomAD constraint metrics (pLI, LOEUF, missense Z) for ODC1 could not be retrieved programmatically for this report and should be looked up directly before being asserted. Note that constraint metrics are of limited interpretive value here, since the disease mechanism is last-exon NMD-escaping GoF rather than haploinsufficiency.
• Germline vs somatic: BABS variants are germline (de novo). Separately, somatic ODC1 alterations occur in sporadic tumors (colorectal, gastric, skin, breast, prostate, neuroblastoma) and are not heritable and not BABS (GeneReviews).
• Functional consequence: Gain of function via loss of degradation. The truncated enzyme retains full catalytic activity; steady-state protein level rises dramatically.

4.4 Allelic disorders — the loss-of-function arm

ODC1 loss-of-function is mechanistically opposite and phenotypically distinct. Prokop et al. characterized p.Gly84Arg (NC_000002.12:g.10444500C>T, rs138359527, NP_002530.1:p.Gly84Arg):

"A functional enzyme assay…showed a 2.5-fold reduction of enzyme activity because of the variant." "The variant was found at the highest allele frequency within South Asian individuals (0.8%, specifically Gujarati Indians in Houston, TX (1.5%) and Punjabi in Lahore, Pakistan (1%)." — Prokop et al., Genes 2021 (PMID:33806076)

Overall gnomAD frequency 0.23%; TOPMed 0.18%; ~3-fold enrichment in Geno2MP, associated with intellectual disability and seizures. The authors propose a bidirectional model:

"…suggesting gain-of-function variants with neural over-proliferation and loss-of-function variants with neural depletion."

This is an important framing for the KB: ODC1 dosage is bidirectionally constrained in brain development.

4.5 Modifier genes

None validated. Mechanistically plausible but untested candidates within the pathway: OAZ1/OAZ2/OAZ3 (antizymes — the very machinery the truncation escapes), AZIN1 (antizyme inhibitor), AMD1, SRM, SMS, SAT1 (catabolic acetylation/export), and the polyamine transport system.

4.6 Epigenetics

• No BABS-specific DNA methylation episignature has been published. (A DNA-methylation episignature screen would be a natural, tractable study.)
• Indirect but relevant: polyamines are decarboxylated-SAM donors and chromatin-associated polycations; the K6/ODC mouse literature shows elevated polyamines "alter chromatin remodeling and cell signaling leading to metabolic reprogramming" (PMID:41925768).
• Regulatory (eQTL) variation at ODC1 is extensive: Prokop et al. identified 900 variants associated with ODC1 expression across 1,414,872 bases around the locus, including rs2302615 (muscle, p=9.4×10⁻⁷) and rs77575195 (tibial nerve, p=8.3×10⁻⁹), "suggesting a high selection on ODC1 expression levels throughout human evolution" (PMID:33806076).

4.7 Chromosomal abnormalities

None reported. BABS is not caused by CNVs, translocations, or aneuploidy. GeneReviews explicitly states gene-targeted deletion/duplication analysis is "not required" given the gain-of-function mechanism — an intragenic deletion would not produce BABS.

5. Environmental Information

• Environmental factors: Not applicable. No toxin, radiation, pollutant, or occupational exposure is implicated in BABS causation.
• Lifestyle factors: Not applicable to causation. Post-diagnosis, caloric management matters for the overgrowth/obesity trajectory, and dietary polyamine restriction is an investigational (unproven) adjunct.
• Infectious agents: Not applicable. No infectious trigger. (Note the ironic pharmacological link in the other direction: eflornithine's original indication is Trypanosoma brucei gambiense African sleeping sickness, where trypanosomal ODC's stability — it lacks the antizyme system, PMID:7730330 — is the drug's selectivity basis.)

6. Mechanism / Pathophysiology

6.1 The causal chain (upstream → downstream)

[MOLECULAR — trigger]
de novo heterozygous 3'-end ODC1 variant (exon 12 / intron 11 splice site)
↓  (last-exon location → escapes nonsense-mediated decay)
[MOLECULAR]
Production of C-terminally truncated ODC protein lacking the 37-residue
degradation domain (aa ~425–461), but retaining full catalytic activity
↓
[MOLECULAR]
Loss of antizyme-stimulated, ubiquitin-INDEPENDENT 26S proteasomal
degradation of ODC  (GO:0010499)
↓
[MOLECULAR]
Cellular accumulation of enzymatically active ODC protein
(12–17× normal activity in dermal fibroblasts; 125–137× in RBCs)
↓
[MOLECULAR / metabolic]
Excess flux: L-ornithine → putrescine  (GO:0009446 putrescine biosynthetic process;
GO:0004586 ornithine decarboxylase activity)
→ putrescine accumulation; compensatory SAT1 acetylation and cellular export
→ elevated plasma N-acetylputrescine and acisoga
↓
[CELLULAR]
Polyamine-driven dysregulation of cell proliferation and differentiation
   ├── neural progenitor over-proliferation / disturbed neurodevelopment
   └── hair follicle outer root sheath keratinocyte dysfunction
↓
[TISSUE]
   ├── Abnormal cortical/white-matter architecture, perivascular space dilation,
   │   periventricular cysts, callosal dysgenesis
   ├── Hair follicle failure → anagen disruption → clumped hair shedding;
   │   follicular cyst formation
   └── Somatic overgrowth / macrocephaly
↓
[ORGANISM]
Global developmental delay, ID, hypotonia, alopecia, dysmorphism,
± epilepsy, ± behavioral phenotypes

Therapeutic interruption point: eflornithine irreversibly inhibits the accumulated ODC enzyme at the first metabolic node, collapsing putrescine production and normalizing downstream metabolites — with demonstrable reversal of hair, tone, developmental, and even white-matter MRI phenotypes.

6.2 Molecular pathway detail

Polyamine biosynthesis (KEGG hsa00330 arginine & proline metabolism; Reactome "Metabolism of polyamines" R-HSA-351202):

L-arginine → L-ornithine (ARG1/ARG2; also LACC1 from L-citrulline)
L-ornithine --[ODC1, PLP-dependent, EC 4.1.1.17]--> putrescine + CO2   ← RATE-LIMITING; the BABS lesion
putrescine + dcSAM --[SRM]--> spermidine
spermidine + dcSAM --[SMS]--> spermine
(catabolic arm: SAT1 acetylation → PAOX/SMOX back-conversion or export)
(spermidine → hypusination of eIF5A via DHPS + DOHH)

The degradation circuit that BABS breaks (this is the mechanistic heart of the disease and is supported by classic, well-quotable primary literature):

"Ornithine decarboxylase (ODC) was converted from a protein with a short intracellular half-life in mammalian cells to a stable protein by truncating 37 residues at its carboxyl terminus. Cells expressing wild-type protein lost ODC activity with a half-life of approximately 1 hour. Cells expressing the truncated protein, however, retained full activity for at least 4 hours…Thus, a carboxyl-terminal domain is responsible for the rapid intracellular degradation of murine ODC." — Ghoda et al., Science 1989 (PMID:2928784)

"…purified 26S proteasome complex, but not the 20S proteasome, catalyses ODC degradation in the absence of ubiquitin. These results strongly suggest that the 26S proteasome, widely viewed as specific for ubiquitin-conjugated proteins, is the main enzyme responsible for ODC degradation." — Murakami et al., Nature 1992 (PMID:1334232)

And the mapping onto BABS:

"Antizyme binds to transient ODC monomer, which results in the exposure of the ODC carboxy (C)-terminal tail that is subsequently recognized by the 26S proteasome for degradation…the final 37 amino-acid residues of the ODC carboxy (C)-terminal tail constitute an ODC destabilization domain that is required for antizyme-stimulated ODC degradation…If absent/deleted, enzymatically active ODC protein is not properly degraded and consequently accumulates in cells." — Bachmann & Bupp 2024 (PMID:37469105)

Note the elegance for KB modeling: the 1989 Ghoda experiment is, in effect, an in vitro pre-enactment of the human BABS allele — the same 37-residue truncation, three decades earlier.

6.3 Cellular processes

6.4 Protein dysfunction

The wild-type ODC monomer is 461 aa; the functional enzyme is an obligate homodimer with two shared active sites (UniProt P11926). BABS variants truncate at residues ~406–448, i.e., after the catalytic core but within the C-terminal degron, which is exactly why the protein is simultaneously stable and active — the worst combination. Prokop et al. note the C-terminus is under strong evolutionary conservation, including a predicted S-farnesylation site at C454, "the most conserved site of all C-terminal amino acids" (PMID:33806076).

This is neither misfolding nor aggregation nor loss of catalysis — it is loss of a degradation signal, a comparatively uncommon disease mechanism worth flagging as such in the KB.

6.5 Metabolic changes

Measured in patients: - RBC ODC enzyme activity: 125–137× control - Primary dermal fibroblast ODC activity: 12–17× control - Putrescine (CHEBI:17148): markedly elevated in fibroblasts and RBCs - Plasma N-acetylputrescine: >97.5th percentile (Z-score vs 866-child reference cohort) - Acisoga [N-(3-acetamidopropyl)pyrrolidin-2-one]: >97.5th percentile - Ornithine (CHEBI:15729) and N-acetylarginine: BELOW the 2.5th percentile at therapy start — consistent with substrate drawdown by the hyperactive enzyme; both normalized on eflornithine (PMID:34282722) - Spermidine (CHEBI:16610) and spermine (CHEBI:15746): "otherwise normal polyamine levels" in plasma clinical metabolomics (PMID:30475435) — an important specificity point: the biochemical signature is putrescine/N-acetylputrescine-selective, not a global polyamine elevation.

"Plasma clinical metabolomics analysis demonstrates elevation of N-acetylputrescine, the acetylated form of putrescine, with otherwise normal polyamine levels." — Rodan et al. 2018 (PMID:30475435)

"…we detected exceptionally high ODC enzyme activity in both primary dermal fibroblasts (12-17-fold of controls) and red blood cells (RBCs) (125-137-fold of controls), using a specific 14C radioactive ODC activity assay." — Schultz et al. 2019 (PMID:31249027)

6.6 Immune system involvement

Not a primary feature of BABS. No immunodeficiency or autoimmunity reported. However, ODC1/polyamine metabolism is deeply embedded in myeloid immunometabolism — LACC1 converts L-citrulline to L-ornithine and "serv[es] as a bridge between proinflammatory nitric oxide synthase (NOS2) and polyamine immunometabolism," with LACC1 phenotypes requiring downstream ODC1 (PMID:35978195); and AhR-driven Odc1 transcription suppresses macrophage pyroptosis via spermine-mediated NLRP3 inhibition (PMID:39113799). These make immune phenotyping of BABS patients a reasonable unexplored question, but there is currently no evidence of clinical immune dysfunction — do not assert one.

6.7 Tissue damage mechanisms

BABS is a developmental/dysregulation disorder rather than a degeneration/necrosis disorder. There is no evidence for oxidative stress, ischemia, fibrosis, or necrosis as primary mechanisms. The tissue-level abnormalities are maldevelopmental (cortical architecture, white matter myelination, follicular structure) and — critically — at least partly reversible, which argues against fixed structural destruction:

"Repeat MRI…demonstrated normalization of the cerebral white matter signal with decrease in volume…resolution of all previously noted cysts." — Rajasekaran et al. 2021 (PMID:34282722)

6.8 Molecular profiling

• Transcriptomics: Prokop et al. mined fetal-brain RNA-seq and cerebral organoid data; ODC1 expression is "markedly elevat[ed] correlating to early development, while neurons/glia progenitors are still proliferating and maturing," and elevated in ventricular zones and in SOX-marker-positive pluripotent/immature cells (PMID:33806076). No BABS patient transcriptome has been published.
• Proteomics: No BABS proteomic dataset. Patient-level protein data are targeted Western blots of ODC (PMID:30239107, PMID:31249027).
• Metabolomics: The best-developed omic layer. Untargeted UPLC-MS clinical metabolomics with Z-scores against an 866-child reference cohort is the established diagnostic/monitoring modality (PMID:34282722). Dansyl-chloride derivatization HPLC is the improved reference method for polyamine quantitation (PMID:40382146); the RP-HPLC + ¹⁴C-ornithine ODC activity protocol is published in detail (PMID:40382142).
• Lipidomics: none.
• Single-cell / spatial: none in BABS patients. Cerebral organoid single-cell data inform the neural-progenitor hypothesis (PMID:33806076).
• Functional genomics screens: No BABS-specific CRISPR/RNAi screen. Extensive ODC1 dependency data exist in DepMap for cancer contexts (not disease-relevant here).

6.9 Cell types and anatomical processes — suggested ontology bindings

7. Anatomical Structures Affected

7.1 Organ level

Primary: - Central nervous system (UBERON:0001017) — the dominant burden: cerebral cortex (UBERON:0000956), cerebral white matter (UBERON:0002316), corpus callosum (UBERON:0002336), periventricular/germinal matrix regions, lateral ventricles (UBERON:0002285), cerebellar vermis (UBERON:0004720), hippocampus (UBERON:0002421), optic chiasm (UBERON:0000959) - Skin and appendages (UBERON:0002097) — hair follicle (UBERON:0002073), scalp (UBERON:0000403), eyebrow (UBERON:0001710), eyelash (UBERON:0001711), nail (UBERON:0001705)

Secondary / systemic: - Musculoskeletal — generalized hypotonia; one case with proximal myopathy and heel/ankle contractures - Craniofacial skeleton — macrocephaly, high forehead, high palate, retrognathia, cupped/large ears - Gastrointestinal — feeding difficulty, aspiration, constipation - Special senses — cochlea/inner ear (sensorineural hearing loss), eye (ptosis, blepharophimosis, refractive error, strabismus) - Genitourinary — cryptorchidism (testis, UBERON:0000473) - Cardiovascular — one prenatal case with ventricular septal defect (PMID:41931584); the index patient had a cutaneous vascular malformation (PMID:30239107). Not established as a recurrent feature. - Hepatic — hepatic calcifications in one case (PMID:37092498); isolated finding

Body systems: nervous, integumentary, musculoskeletal, digestive, sensory; cardiovascular and hepatobiliary only anecdotally.

7.2 Tissue and cell level

• Hair follicle epithelium, specifically outer root sheath keratinocytes (CL:0002561) — the cell type in which the K6 promoter drove ODC in the transgenic mouse that phenocopies BABS skin/hair
• Neural progenitor cells (CL:0011020) / radial glia (CL:0000681) of the ventricular and subventricular zones
• Oligodendrocytes / myelinating glia — implicated by the white-matter signal abnormalities and their normalization on treatment
• Dermal fibroblasts (CL:0002620) and erythrocytes (CL:0000232) — biochemically abnormal and diagnostically accessible

7.3 Subcellular level

• Cytosol (GO:0005829) — ODC is a cytosolic enzyme; this is where the pathological accumulation occurs
• Proteasome complex (GO:0000502), specifically the 26S proteasome — the machinery whose substrate recognition is evaded
• Nucleus (GO:0005634) — polyamines are chromatin-associated polycations

7.4 Localization / lateralization

Brain findings are predominantly bilateral (bilateral paraventricular cysts, bilateral perivascular space dilation, diffuse white matter change), though asymmetric/unilateral lesions occur (right subependymal cyst; focal polymicrogyria; porencephalic cyst). Alopecia is diffuse/generalized with occasional preserved tufts — e.g., "scalp alopecia outside of tuft of long and coarse hair on central posterior scalp" (PMID:37092498).

8. Temporal Development

8.1 Onset

• Prenatal: polyhydramnios (55–80%), decreased fetal movement, and — in the 2026 report — second-trimester macrocephaly and VSD detectable by ultrasound (PMID:41931584). Prenatal ventriculomegaly and cerebral cysts have been detected (PMID:37092498).
• Birth: macrosomia/large for gestational age, macrocephaly at birth, hair present (may be sparse or atypically colored), congenitally absent/sparse eyebrows and eyelashes.
• Neonatal: hypotonia, feeding difficulty, hypoglycemia, hyperbilirubinemia; respiratory distress with NICU stay in one case.
• First weeks of life: the defining event — hair loss in large clumps (HP:0003623 Neonatal onset / HP:0011463 Childhood onset for later features).
• Infancy onward: developmental delay becomes evident.
• Adolescence/adulthood: late-onset epilepsy possible (age 14 in the one reported case).

Onset pattern: congenital/insidious, not acute. Suggested HPO onset term: HP:0003577 Congenital onset for the syndrome; HP:0003623 Neonatal onset for the alopecia.

8.2 Progression

• Stages: no formal staging system exists.
• Progression rate: the neurodevelopmental phenotype is static-with-slow-acquisition, not neurodegenerative. Skills are gained slowly (walking 17 months–4 years) rather than lost. One patient showed progressive motor decline with myopathy and loss of ambulation over 12 years, indicating that a subset may have a progressive motor course (PMID:37092498).
• Course pattern: chronic, lifelong, generally non-progressive on the cognitive axis; epilepsy, when present, can be progressive and refractory.
• Duration: lifelong.

8.3 Patterns

• Remission: no spontaneous remission. Treatment-induced improvement is well documented — hair regrowth by 1–2 months of eflornithine, motor gains by 4 months, MRI normalization by ~6 months, sustained at >3 years (PMID:34282722, PMID:37469105).
• Critical periods: This is the most clinically consequential open question. The mouse data are unusually informative here:

"The ODC inhibitor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if administered before the onset of ODC overexpression. 2-Difluoromethylornithine could also reactivate hair growth in animals with complete hair loss." — Soler et al., J Invest Dermatol 1996 (PMID:8618048)

That is: for the follicular phenotype, both prevention and rescue are achievable. Whether the same holds for the neurodevelopmental phenotype — and whether there is a closing window for cortical/white-matter benefit — is unknown and is the central natural-history question for the field. The prenatal-diagnosis capability now demonstrated (PMID:41931584) makes very-early or even prenatal intervention a live question.

9. Inheritance and Population

9.1 Epidemiology

• Prevalence: UNKNOWN. GeneReviews: "The prevalence of Bachmann-Bupp syndrome is unknown."
• Cumulative reported cases (a moving target — cite the year):

• Best current statement: ~12 published cases; ~18–20 known worldwide across ≥8 countries as of 2026. Suggested prevalence_class: BELOW_1_IN_1000000 with measure_type: CASES_IN_LITERATURE and prevalence_class: NOT_YET_DOCUMENTED as an alternative honest encoding.
• Incidence: not estimable.
• Ascertainment caveat: BABS is diagnosable only by sequencing, and the phenotype (DD + alopecia) is distinctive enough that it is likely under-ascertained rather than over-ascertained. Expect the count to rise with exome/genome uptake.

9.2 Inheritance genetics

• Pattern: Autosomal dominant (HP:0000006), essentially always de novo.

  "All probands reported to date with BABS whose parents have also undergone molecular genetic testing have the disorder as the result of a de novo ODC1 pathogenic variant." — GeneReviews (PMID:36007106)

• Penetrance: Believed complete (100%) — but note this is inferred from a tiny, ascertainment-biased de novo case series with no transmitted families; treat "100% penetrance" as provisional.
• Expressivity: Variable — spanning nonverbal severe ID to a 12-year-old who reads and writes; epilepsy in only ~8%; macrocephaly in only 66–75%.
• Genetic anticipation: Not applicable (not a repeat expansion).
• Germline mosaicism: Not documented, but assumed possible; drives the recurrence-risk counseling figure.
• Recurrence risk:
• Parents test negative → ~1% sibling recurrence risk (germline mosaicism allowance)
• A parent carries the variant → 50%
• Offspring of an affected individual → 50% (no reported reproduction to date)
• Founder effects: None. All variants are private de novo events; the only recurrence (c.1242-2A>G in ≥3 individuals) reflects a mutational hotspot at a canonical splice acceptor, not a shared haplotype.
• Consanguinity: No role — dominant de novo mechanism.
• Carrier frequency: Not applicable.

9.3 Population demographics

• Ethnic/ancestry predilection: None known. Cases span eight countries (PMID:41410504), including the US, EU, and a Chinese prenatal case (PMID:41931584). The index case was described as Caucasian; no ancestry enrichment has been reported.
• Geographic distribution: worldwide, no clustering. Apparent geographic distribution reflects where genomic sequencing and the ICPD network reach, not true biology.
• Sex ratio: Reported cases include both sexes (the index case and several others are female; the 23-year-old epilepsy case is male; HPOA lists cryptorchidism in 2/3 males). No sex bias is established; the sample is far too small to estimate a ratio. Do not assert one.
• Age distribution: reported ages at description range from prenatal/12 months to 23 years. No adult natural-history data beyond age 23.

10. Diagnostics

10.1 Suggestive clinical findings (GeneReviews)

Consider BABS in an individual with: 1. "An unusual pattern of noncongenital alopecia due to sudden-onset hair loss shortly after birth" — the single most specific pointer 2. Developmental delay, typically moderate to severe 3. Hypotonia 4. Supportive: "metabolomic profile showing abnormal polyamine pathway metabolites, including increased N-acetylputrescine"

10.2 Establishing the diagnosis

Requires all three of: consistent clinical/laboratory findings + a heterozygous pathogenic/likely pathogenic ODC1 variant + abnormal polyamine-pathway metabolomics. "Heterozygous pathogenic variants in ODC1 that cause BABS are typically gain-of-function variants."

10.3 Genetic testing

Reference sequence for reporting: NM_002539.3 / NP_002530.1.

10.4 Biochemical / omics diagnostics — the BABS-distinctive layer

BABS is one of the few neurodevelopmental disorders with a directly measurable, treatment-responsive enzymatic biomarker. Three assays:

1. Plasma untargeted clinical metabolomics (UPLC-MS) with Z-scores vs a pediatric reference cohort (n=866). Signature: ↑ N-acetylputrescine, ↑ acisoga, ↓ ornithine, ↓ N-acetylarginine — with normal spermidine/spermine. Suitable for both diagnosis and treatment monitoring (PMID:34282722).
2. ODC enzyme activity assay — ¹⁴C-ornithine radioassay on red blood cells (125–137× control) or primary dermal fibroblasts (12–17× control). Detailed protocol published (PMID:40382142). This is the assay that adjudicates VUSs (PMID:40167220).
3. Polyamine quantitation by RP-HPLC with dansyl chloride derivatization (PMID:40382146).

Also: Western blot for ODC protein in RBCs/fibroblasts (elevated).

Sample collection, shipment, consent, and biobanking protocols for international polyaminopathy patients are published (PMID:40382145) and coordinated through the ICPD.

10.5 Imaging, electrophysiology, other clinical tests

• Brain MRI — abnormal in nearly all; no pathognomonic pattern. Findings listed in §3.4. MRI also serves as a treatment-response readout (white matter normalization, cyst resolution).
• Prenatal ultrasound — polyhydramnios, macrocephaly, ventriculomegaly, cerebral cysts, VSD; can prompt prenatal diagnosis (PMID:41931584).
• EEG — indicated only if seizures are suspected.
• EMG/NCS — one patient's proximal myopathy was identified by EMG (PMID:37092498).
• Audiology (sensorineural hearing loss) and ophthalmology (refractive error, strabismus, ptosis) — annually.
• Skin biopsy — for fibroblast culture (research/functional assay), not for histopathology per se. No diagnostic histopathologic signature has been defined; follicular cysts are the notable dermatopathologic finding.
• Echocardiogram — only if a cardiac anomaly is suspected; not routine.

10.6 Differential diagnosis (GeneReviews Table 3)

Also worth listing: other polyaminopathies — Snyder-Robinson syndrome (SMS, X-linked, ~63% epilepsy, no alopecia), Faundes-Banka syndrome (EIF5A), DHPS deficiency, DOHH disorder. Per the 2026 review, macrocephaly + non-congenital alopecia is what separates BABS from the other four:

"The majority of patients (9/12, 75%) also presented with macrocephaly, which would be considered a distinctive feature of BABS, as this was not reported in any patients with DHPS deficiency, FABAS, or DOHH disorder." (PMID:41410504)

10.7 Screening of asymptomatic individuals

• Newborn screening: BABS is not on any NBS panel. It is, however, an intriguing theoretical candidate given (a) a measurable metabolite in blood and (b) an available treatment with a possible early-intervention window — but no NBS pilot exists and this should be framed as a hypothesis, not a recommendation.
• Carrier screening: not applicable (de novo dominant).
• Cascade screening: not applicable in practice; parental testing is done to establish de novo status and refine recurrence risk.

11. Outcome / Prognosis

11.1 Survival and mortality

• No BABS-specific mortality data, survival curves, or life-expectancy estimates exist. The oldest reported patient is 23 years. No deaths have been reported in the published series. Do not assert a life expectancy.
• Mortality risk, where present, would be expected to derive from aspiration/feeding complications and refractory epilepsy, not from a disease-intrinsic lethal process.

11.2 Morbidity and function

• Dominant morbidity: moderate-to-severe intellectual disability, motor delay/hypotonia, communication impairment (three individuals nonverbal at last report), feeding difficulty, and — in one long-followed patient — loss of independent ambulation.
• Functional range is wide: from nonverbal and wheelchair-dependent to literate with moderate ID.
• Disability outcomes: lifelong need for special education, PT/OT/SLP, and in some cases assistive mobility and enteral feeding.
• No validated QoL instrument data. (ICF-based functional characterization has not been done.)

11.3 Complications

Aspiration and recurrent respiratory events; refractory epilepsy (rare but severe); constipation; obesity secondary to overgrowth; recurrent follicular cysts requiring dermatologic/surgical drainage; refractive error/strabismus; sensorineural hearing loss; contractures/orthopedic sequelae of hypotonia and immobility.

11.4 Cancer risk — an unresolved, important question

ODC1 is a canonical c-Myc target and proto-oncogenic driver; K6/ODC mice develop spontaneous skin tumors (PMID:7671221) and are so tumor-prone they are used as a carcinogen-detection bioassay (PMID:10906419). Somatic ODC1/polyamine dysregulation is pervasive in human cancer.

Rodan et al. therefore raised surveillance explicitly:

"As the ODC1 gene has been implicated in neoplasia, cancer surveillance may be important in this disorder." (PMID:30475435)

However: no malignancy has been reported in any individual with BABS to date, GeneReviews' surveillance table does not include cancer screening, and the 2025 treatment review documents no cancer-monitoring protocol. With ~18 patients and a maximum reported age of 23, the cohort is far too small and young to detect an elevated cancer risk.

Recommended KB framing: encode this as an open mechanistic hypothesis / knowledge gap (kind: KNOWLEDGE_GAP, or HUMAN_MODEL_MISMATCH — strong mouse tumor phenotype, no human confirmation), not as an asserted phenotype. Note the pleasing irony that the treatment (DFMO) is itself an established chemopreventive agent (colorectal adenoma prevention, NCT00118365), so treated patients may be incidentally protected.

11.5 Recovery potential and prognostic factors

• Recovery potential is genuinely favorable on treatment and this is the single most important prognostic modifier known:

  "She demonstrated remarkable improvement in both neurological symptoms and cortical architecture. She gained fine motor skills with the capacity to feed herself and sit with support." (PMID:34282722) "Treated patients have consistently shown improvement in muscle tone, developmental milestones, and hair regrowth." (PMID:40167220)

• Prognostic factors (all inferred, none validated): age at treatment initiation; presence of refractory epilepsy; severity of baseline structural brain abnormality; feeding/aspiration status.
• Prognostic biomarkers: N-acetylputrescine Z-score and RBC ODC activity are pharmacodynamic markers with demonstrated normalization on therapy; whether they predict developmental outcome is untested.

12. Treatment

12.1 Targeted therapy — eflornithine (DFMO): the flagship

Documented outcomes (index patient, Rajasekaran 2021 / Bachmann 2024):

"This work highlights the strategy of repurposing drugs to treat a rare disease." — Rajasekaran et al. 2021 (PMID:34282722)

Caveats to encode honestly: all outcome data are uncontrolled single-arm case reports (n≤6) with no blinding, no comparator, and no pre-specified endpoints. Developmental gains in a young child on intensified therapy services are confounded. The MRI and metabolite changes are the most objective evidence. There is no randomized or controlled trial of DFMO in BABS, and none is registered on ClinicalTrials.gov (searches for BABS/ODC1/polyaminopathy return only oncology and chemoprevention DFMO trials: NCT00118365, NCT00086736, NCT03536728).

12.2 Other pharmacotherapy / investigational

• Other ODC inhibitors and DFMO analogs — listed by GeneReviews as under investigation.
• Polyamine transport inhibitors — e.g., AMXT 1501, studied with DFMO in oncology (NCT03536728); mechanistically rational for BABS (blocking uptake of dietary/microbial polyamines that could bypass ODC inhibition) but untested in BABS.
• Polyamine-restricted diet — investigational (GeneReviews).
• Gut-flora-directed antibiotics to reduce luminal polyamine production — proposed by Rodan et al. (PMID:30475435); never tested.
• Anti-seizure medications — standard; note one reported case refractory to multiple agents and the ketogenic diet.

12.3 Advanced therapeutics

• Gene therapy / gene editing: none developed. Conceptually, BABS is an allele-selective knockdown target (ASO or siRNA against the mutant allele) rather than a gene-replacement target — the pathology is a toxic stabilized protein, not absent protein. No such program exists. Note the KB's antisense_oligonucleotide_therapy module RNase-H-knockdown paradigm would be the natural conceptual fit if one were ever developed.
• Cell therapy, RNA therapy, immunotherapy: none; not applicable.
• Pharmacogenomics: no PharmGKB/CPIC guidance for eflornithine relevant to BABS.

12.4 Supportive, rehabilitative, and surgical management (GeneReviews Table 5)

12.5 Surveillance (GeneReviews Table 6)

Notably absent from GeneReviews surveillance: cancer screening (see §11.4).

12.6 Treatment strategy

No formal algorithm exists. In practice: 1. Confirm diagnosis (variant + metabolomics + ODC activity — the latter is decisive for VUSs). 2. Institute full multidisciplinary supportive/rehabilitative care immediately. 3. Refer to the ICPD for biochemical characterization and biobanking. 4. Pursue eflornithine via single-patient IND (US) or off-label pathway; escalate 500 → 750 → 1000 mg/m² BID. 5. Monitor pharmacodynamically (N-acetylputrescine Z-score, RBC ODC activity) and clinically (hair, tone, milestones, MRI); monitor for DFMO class toxicity including audiometry and CBC.

Personalized-medicine framing: BABS is a genuine N-of-1-to-N-of-6 precision medicine exemplar — genotype-directed, biomarker-monitored, mechanism-matched.

13. Prevention

13.1 Primary prevention

Not possible. BABS arises from de novo germline variants with no known modifiable determinant. There is no vaccination, no risk-factor modification, and no environmental lever.

13.2 Secondary prevention (early detection)

• Genomic: early ES/GS in an infant with the DD + post-natal clumped alopecia gestalt is the practical early-detection route.
• Biochemical: plasma N-acetixputrescine on clinical metabolomics can flag the diagnosis; hypothetically a newborn-screening analyte, but no NBS program or pilot exists — this is speculation, not policy.
• Prenatal: the 2026 report demonstrates that second-trimester ultrasound findings (macrocephaly, VSD) can trigger prenatal molecular diagnosis (PMID:41931584), and polyhydramnios/ventriculomegaly/cerebral cysts are recurrent prenatal signals.
• Rationale for early detection is unusually strong here because a mechanism-matched treatment exists and mouse data show pre-onset DFMO prevents the follicular phenotype (PMID:8618048).

13.3 Tertiary prevention

This is where the actionable prevention lives: eflornithine to prevent progression/persistence of alopecia, hypotonia, follicular cysts, and possibly white-matter injury; aspiration precautions and feeding management; seizure control; caloric management to prevent obesity; annual skin/eye/ear surveillance.

13.4 Genetic screening and counseling

• Genetic counseling (NCIT:C15240) is indicated for every family: confirm de novo status by parental testing; counsel ~1% sibling recurrence if parents are negative (germline mosaicism), 50% if a parent carries the variant, 50% for offspring of an affected individual.
• Prenatal diagnosis and preimplantation genetic testing (PGT-M) are technically available once the familial variant is known: "Given this risk, prenatal and preimplantation genetic testing may be considered." (GeneReviews)
• Carrier screening / population genetic screening: not applicable.

13.5 Immunization, public health, environmental interventions, prophylaxis

• Immunization: routine childhood immunizations only; no disease-specific vaccine strategy. No contraindication known.
• Public health / environmental interventions: not applicable.
• Prophylaxis: no antimicrobial or other prophylaxis indicated. (Prophylactic antibiotics to suppress gut polyamine production is a mechanistic proposal, not a recommendation.)

14. Other Species / Natural Disease

14.1 Taxonomy and orthology

The C-terminal degron is highly evolutionarily conserved — the predicted farnesylation site C454 is conserved in 215/220 sequences analyzed (PMID:33806076).

14.2 Natural disease in other species

None reported. There is no OMIA entry for a naturally occurring ODC1 disorder in companion animals, livestock, or wildlife found in this search. BABS-equivalent disease in animals exists only as engineered models. Veterinary relevance: nil.

14.3 Comparative biology

The comparative story is unusually clean and is the strongest cross-species evidence in the file: - The K6/ODC transgenic mouse (constitutive ODC in hair-follicle outer root sheath keratinocytes near the bulge stem cell niche) develops alopecia, dermal follicular cysts, excessive skin wrinkling, and enhanced nail growth — i.e., the exact dermatologic tetrad of BABS, including the follicular cysts and nail changes. - Bupp et al. framed the index human case explicitly against this:

"This is the first human case confirming similar symptoms observed in a transgenic ODC1 mouse model first described over 20 years ago." (PMID:30239107) - Evolutionary conservation of the mechanism is complete: the 37-residue C-terminal degron, antizyme-stimulated ubiquitin-independent 26S degradation, and DFMO sensitivity are all conserved mouse↔human. - Divergence: Trypanosoma brucei lacks antizyme-mediated ODC degradation entirely, which is why DFMO is a trypanocide — a natural "phenocopy" of the BABS lesion at the organismal level.

14.4 Transmission

Not applicable. BABS has no zoonotic potential and no cross-species transmissibility.

15. Model Organisms

15.1 The K6/ODC transgenic mouse — the phenocopy model

Construct: bovine keratin 6 promoter driving a mutated ODC transgene in outer root sheath keratinocytes (CL:0002561) of the hair follicle near the bulge stem cell niche. Model type: mammalian, transgenic (gain-of-function overexpression).

Phenotype recapitulation — excellent for the ectodermal arm:

"Effects observed include development of dermal follicular cysts, excessive skin wrinkling, enhanced nail growth, alopecia, and spontaneous tumor development. These results indicate that up-regulation of polyamine biosynthesis can profoundly disturb skin homeostasis and alter susceptibility to neoplastic development." — Megosh et al., Cancer Res 1995 (PMID:7671221)

"These transgenic mice have a normal first hair cycle, but lose their hair completely beginning 2-3 wk after birth… The ODC inhibitor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if administered before the onset of ODC overexpression. 2-Difluoromethylornithine could also reactivate hair growth in animals with complete hair loss. Our results suggest that ODC is an important regulatory gene for the mouse hair follicle." — Soler et al., J Invest Dermatol 1996 (PMID:8618048)

Note the striking temporal parallel: mice have a normal first hair cycle then lose hair at 2–3 weeks; BABS infants have hair at birth then shed it in clumps within weeks.

Putrescine — not spermidine/spermine — is the effector, matching the human metabolomic signature:

"The regulatory polyamine in this model appears to be putrescine, the immediate product of ornithine decarboxylase." — Peralta Soler et al., Cancer Res 1998 (PMID:9563478)

Model limitations: (a) expression is skin/follicle-restricted (K6 promoter), so the model does not recapitulate the neurodevelopmental, macrocephaly, hypotonia, or brain-imaging phenotypes — the dominant human morbidity; (b) it is an overexpression model, not a knock-in of the human degron truncation, so the stoichiometry and cell-type distribution differ; (c) the tumor phenotype is prominent in mice but has not been observed in humans with BABS, a genuine human-model mismatch that should be recorded as such rather than translated forward.

Applications: hair-cycle biology; DFMO prevention-vs-rescue timing (directly informs the human critical-period question); skin carcinogenesis; and — as a 30-year retrospective published in 2026 — mechanisms of polyamine-promoted tumorigenesis including stem-cell recruitment, chromatin remodeling, metabolic reprogramming, angiogenesis, and immune modulation (PMID:41925768). Also validated as a sensitive carcinogen-identification bioassay (PMID:10906419).

15.2 The Odc1 knockout mouse — the loss-of-function arm

"Embryonic day E3.5 ODC-deficient embryos were capable of uterine implantation and induced maternal decidualization yet failed to develop substantially thereafter… loss of ODC does not affect cell growth per se but rather is required for survival of the pluripotent cells of the inner cell mass. Therefore, ODC plays an essential role in murine development." — Pendeville et al., Mol Cell Biol 2001 (PMID:11533243)

Odc1^-/-^ is embryonic lethal (peri-implantation); Odc1^+/-^ heterozygotes are "viable, normal, and fertile." This is directly relevant: it shows that (a) ODC1 haploinsufficiency does not produce BABS, reinforcing that BABS is GoF; and (b) complete ODC ablation is not survivable — which sets a theoretical floor on how aggressively ODC can be inhibited therapeutically (though DFMO's clinical safety record indicates a wide window).

15.3 Cellular and in vitro models

• Patient-derived primary dermal fibroblasts — the best-characterized BABS cell model. Show 12–17× ODC activity, elevated ODC protein and putrescine; DFMO exposure "reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death" (PMID:31249027). This is the in vitro proof-of-concept that directly justified the human trial-of-one — an exemplary bench-to-bedside chain.
• Patient RBCs — 125–137× ODC activity; a non-invasive biomarker source.
• Cerebral organoids (not patient-derived) — used to link ODC1 expression to neural progenitor proliferation (PMID:33806076).
• The 1989 Ghoda C-terminal truncation construct (PMID:2928784) is, retrospectively, the founding in vitro model of the BABS lesion.

15.4 Models that do NOT exist (gaps)

• No knock-in mouse carrying a human BABS ODC1 C-terminal truncation allele — this is the most conspicuous missing model, and the only one that could address the neurodevelopmental phenotype and treatment-window question.
• No BABS zebrafish model (in contrast to DHPS deficiency, which has one).
• No patient-derived iPSC or iPSC-derived neuron/organoid model.
• No conditional/neural-specific ODC overexpression model.
• No MorPhiC ODC1 null-allele dataset identified.

15.5 Model resources

MGI (mouse), IMPC/KOMP (for Odc1 alleles), Alliance of Genome Resources, ZFIN, IMSR/JAX for strain availability. The ICPD (Corewell Health / Michigan State University / Snyder-Robinson Foundation) is the primary human-sample and biobanking resource (PMID:37092498, PMID:40382145).

Curation Notes: Evidence Classification and Verification Flags

Evidence-source tagging for KB items

Do not let model-organism evidence stand alone for human phenotypes. The K6/ODC skin-tumor phenotype in particular must not be carried into the human entry as a phenotype; encode it as a HUMAN_MODEL_MISMATCH discussion.

Items requiring verification before commit

1. c.1342A>T vs c.1342A>G for the index variant — use A>T (primary source + ClinVar VCV000983289).
2. Protein HGVS for c.1242_1263del22 and c.1313_1316delCTGT — the extracted protein annotations do not reconcile with the cDNA positions. Re-derive from the source tables.
3. VanSickle 2026 frequency percentages — internally inconsistent as extracted (11/12 rendered as 83.3%). Prefer GeneReviews Table 2 as the frequency source; re-verify the 2026 table directly.
4. gnomAD constraint metrics for ODC1 — not retrieved; look up directly if needed (and note their limited relevance to a last-exon GoF mechanism).
5. ICD-11 code — not confirmed; do not assert.
6. MGI:97402 for mouse Odc1 — not verified in this session.
7. HP:0025249 "Follicular cyst" — term ID not verified via OAK; run just validate-terms before commit.
8. CL:0011020 label casing — OLS returned "Neural progenitor cell"; confirm canonical label with OAK.
9. Sex ratio — do not assert; the sample is too small.
10. Cancer risk — encode as knowledge gap, not phenotype.

Suggested module conformance

BABS does not map cleanly onto an existing kb/modules/ entry. The closest conceptual neighbors are metabolic_intoxication_decompensation (an enzymatic block in intermediary metabolism) — but BABS is a chronic overproduction, not an episodic catabolic-stress decompensation, so conformance would be a poor fit. Consider instead that BABS, Snyder-Robinson syndrome, Faundes-Banka syndrome, DHPS deficiency, and DOHH disorder together justify a new polyamine_pathway_dysregulation module and/or a Polyaminopathies Grouping (grouping_basis: SHARED_PATHWAY, with a NECESSARY HAS_BIOLOGICAL_PROCESS criterion on polyamine metabolic process) — the 2026 systematic review (PMID:41410504) is purpose-built as the curated rationale for exactly such a grouping.

Sources

Primary literature (PubMed): - Bupp CP et al. Am J Med Genet A 2018 — PMID:30239107 - Rodan LH et al. Am J Med Genet A 2018 — PMID:30475435 - Schultz CR et al. Biochem J 2019 — PMID:31249027 - Prokop JW et al. Genes (Basel) 2021 — PMID:33806076 - Rajasekaran S et al. eLife 2021 — PMID:34282722 - VanSickle EA et al. Am J Med Genet A 2021 — PMID:34477286 (correction: PMID:37078542) - Bupp C, VanSickle E, Bachmann AS. GeneReviews 2022 — PMID:36007106 / NBK583220 - Afrin A et al. Pediatr Dermatol 2023 — PMID:36443247 - Michael J et al. Med Sci (Basel) 2023 — PMID:37092498 - Bachmann AS, Bupp CP. Dev Med Child Neurol 2024 — PMID:37469105 - Wu B et al. Int J Mol Sci 2024 — PMID:38928047 - Bupp CP et al. Am J Med Genet C 2025 — PMID:40167220 - Schultz CR et al. Methods Enzymol 2025 — PMID:40382142 - VanSickle EA et al. Methods Enzymol 2025 — PMID:40382145 - Nwafor A et al. Methods Enzymol 2025 — PMID:40382146 - VanSickle EA et al. Am J Med Genet A 2026 — PMID:41410504 - Li R et al. Prenat Diagn 2026 — PMID:41931584 - Gilmour SK et al. Amino Acids 2026 — PMID:41925768

Mechanism / model organism: - Ghoda L et al. Science 1989 — PMID:2928784 - Murakami Y et al. Nature 1992 — PMID:1334232 - Megosh L et al. Cancer Res 1995 — PMID:7671221 - Hua SB et al. J Biol Chem 1995 — PMID:7730330 - Soler AP et al. J Invest Dermatol 1996 — PMID:8618048 - Peralta Soler A et al. Cancer Res 1998 — PMID:9563478 - Chen Y et al. Toxicol Lett 2000 — PMID:10906419 - Pendeville H et al. Mol Cell Biol 2001 — PMID:11533243 - Wei Z et al. Nature 2022 (LACC1–NOS2–ODC1) — PMID:35978195

Databases: - OMIM 619075 / 165640 · MONDO:0033642 (Monarch) · MedGen C5436741 · Orphanet 544488 · NCBI Gene 4953 (ODC1) · UniProt P11926 · HPO annotations, OMIM:619075 · ClinVar VCV000983285–983289, VCV001074405 · NORD · Wikipedia · ClinicalTrials.gov (NCT00118365, NCT00086736, NCT03536728 — DFMO oncology/chemoprevention only; no BABS trial registered)

PubMed metadata and abstracts in this report were retrieved via NCBI E-utilities and PubMed Central; DOIs are listed where retrieved.